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ABSTRACT: Modulation of protein−protein interactions
(PPIs) with small molecules has been hampered by a lack of
lucid methods capable of reliably identifying high-quality hits.
In fragment screening, the low ligand efficiencies associated
with PPI target sites pose significant challenges to fragment
binding detection. Here, we investigate the requirements for
ligand-based NMR techniques to detect rule-of-three compliant
fragments that form part of known high-affinity inhibitors of
the PPI between the von Hippel−Lindau protein and the alpha
subunit of hypoxia-inducible factor 1 (pVHL:HIF-1α). Careful
triaging allowed rescuing weak but specific binding of fragments that would otherwise escape detection at this PPI. Further
structural information provided by saturation transfer difference (STD) group epitope mapping, protein-based NMR, competitive
isothermal titration calorimetry (ITC), and X-ray crystallography confirmed the binding mode of the rescued fragments. Our
findings have important implications for PPI druggability assessment by fragment screening as they reveal an accessible threshold
for fragment detection and validation.
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Protein−protein interactions (PPIs) and interfaces arepreponderant in nearly every facet of cellular function,
exhibiting a wide range of topologically complex and diverse
interactions.1−4 The recognized value of modulating PPIs for
therapeutic intervention have led to recent efforts, both in
academic and pharmaceutical research, to target them using drug-
like small molecules.5−8 However, to date, this has remained a
frustratingly slow and difficult goal to achieve, in part due to
challenges in identifying high-quality starting hits.1,9 Nevertheless,
several small molecules have been developed to bind PPI sites
with desired levels of affinity, yet they tend to be much larger, on
average, than compounds targeting more classical binding sites
and, as a result, exhibit much lower ligand efficiency (LE), i.e.,
binding free energy per heavy atoms.10
To aid more successful targeting of PPIs, it is important to
focus efforts onto those PPIs that are most likely to yield high-
quality, high-LE small molecule binders, i.e., exhibit highest
druggability.11,12 Several approaches are being used to assess
target propensity to ligand binding, including computational
methods based on three-dimensional structures of the
target.13−15 A method that is being increasingly used for this
purpose is biophysical fragment screening.11 On the one hand,
fragment screening can be performed on any protein targets
that are readily expressed recombinantly without requiring in
principle prior structural information on the target. On the other
hand, the lower LEs typically associated with small molecule
binding at PPIs raise the barrier to the detection of bona fide low-
affinity fragment hits. One way to approach this challenge would
be to screen larger compounds.16,17 The problem associated with
this strategy is that larger compounds will inevitably explore
chemical space less efficiently than the smaller fragments, and
as a result, larger libraries would be required. However, a more
general and simpler approach would be to increase the sensitivity
of binding detection in a fragment screen. Here, we interrogate
for the first time the low limits of fragment binding detection
using a successfully targeted PPI as a model system.
Our recent discovery of high-affinity, lead-like small molecule
inhibitors of the interaction between the von Hippel−Lindau
protein (pVHL) and the alpha subunit of hypoxia-inducible
factor 1 (HIF-1α) has revealed this PPI to be druggable.17−19
The compounds were designed using a crystal structure of HIF-
1α peptide bound to the stable multiprotein complex pVHL-
ElonginC:Elongin B (VCB) (Figure 1). Surprisingly, however,
we could not detect binding of the constitutive Rule-of-three
(Ro3)20 compliant fragments of our inhibitors (molecular weight
< 300, ClogP < 3, the number of hydrogen bond donors and
acceptors each should be <3, and the number of rotatable bonds
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should be <3).17 Moreover, a screen of ∼1300 Ro3 obeying
fragments library proved unsuccessful for targeting the
pVHL:HIF-1α interface.17 We were intrigued by these observa-
tions, in part because there is a growing belief that target
druggability correlates with hit rates from fragment screening.11
To resolve this conundrum, we decided to investigate the ability
to triage bona fide weak binding fragments using ligand-based
NMR spectroscopy, arguably one of the most sensitive
biophysical techniques that is widely applied to hit generation
in drug discovery.21
A library of 12 compounds was designed by defragment-
ing known inhibitors 1 and 2 (see Figures S1 and S3,
Supporting Information),18,19 and screened against the target
protein using three distinct ligand-based 1D 1H NMR experi-
ments (Table 1): first, saturation transfer difference (STD)22
experiments apply a selective pulse to saturate protein
resonances. Only ligands that bind to the protein will receive
saturation transfer, resulting in their signals to appear as positive
in a difference spectrum between the unsaturated and saturated
spectra; second, Carr−Purcell−Meiboom−Gill (CPMG)23
experiments exploit the faster T2 relaxation times of macro-
molecules relative to small molecules. Upon binding to the
protein, ligands relaxation time will decrease, causing a line
broadening and a consequent decrease in intensity on their
signals; finally, the water-ligand observed via gradient spectros-
copy (WaterLOGSY)24 experiments apply a selective pulse to
saturate resonances of water molecules. In the absence of protein,
cross-relaxation from water will yield control ligand signals that
are phased downward; in the presence of protein, small molecule
binders will receive an NOE contribution from water that is of
opposite sign relative to control, resulting in their signals either
showing a reduction in intensity, or even pointing upward.
Experimental conditions of 1 mM ligand and 10 μM protein,
which are typically used in NMR fragment screening, enabled
unambiguous detection in each of the three NMR experiments of
the larger, Ro3-breaking compounds 3−5 (set-up 1, Table 1).
We were also able to characterize binding thermodynamics by
isothermal titration calorimetry (ITC) and determine bound
X-ray structures by crystallographic soaks, confirming the
expected binding modes at the HIF-1α site (Table 1, Figures 2
and S4−S5, Supporting Information). In contrast, binding
detection was unfruitful for Ro3-compliant fragments 6−12
under set-up 1 (Table 1 and Figures S6−12a−c, Supporting
Information). This observation is consistent with our pre-
vious results,17 raising the question whether this is due to the
absence of binding (true negative) or limitations of the screening
setup at detecting weak binding (false negative).
To extend the binding detection range, we set to modify the
NMR experimental conditions by first increasing the protein
concentration to 40 μMwhile maintaining ligand concentrations
fixed at 1mM(setup 2); and second by increasing concentrations
of protein and ligand to 30 μM and 3 mM (set-up 3), res-
pectively, thereby maintaining a protein/ligand excess of 100-
fold as in set-up 1.
We first applied the revised set-ups to the capped hydroxypro-
line (Hyp) core fragment 6, that had successfully yielded an
X-ray bound structure17 but had otherwise proven elusive to
biophysical detection. Each NMR experiment distinctly detected
binding of 6 under both set-ups 2 and 3 but not set-up 1, placing
this compound as a true positive hit (Figures 3 and S6,
Supporting Information).
Set-up 2 provided the most reliable detection profile for 6
in CPMG and WaterLOGSY, a direct result of increasing the
fractional bound ligand, while maintaining total ligand
concentration constant at 1 mM. In contrast, set-up 3 gave the
best result in STD, as this technique is unaffected by increasing
free ligand concentration. Similarly, we were able to un-
ambiguously detect binding of compounds 8−11 to VCB,
whereas binding of compounds 7 and 12 remained undetected
under each revised setup (Table 1 and Figures S7 and S12,
Supporting Information). This highlighted that the newly
adopted set-ups enable robust discrimination between true
binders and nonbinders, which is a critical requisite in biophysical
fragment screening.
Aiming further characterization of the rescued binders, we
asked if they targeted specifically the pVHL-HIF-1α interface
and whether they would recapitulate the binding mode shown
as part of the intact parent compounds 1 and 2. To address this,
we first attempted to compete binding of 6 and 8−11 using a
high-affinity 19-mer HIF-1α peptide. Compounds 6, 8, and 11
were displaced by the peptide, placing them at this PPI (Table 1
and Figures S6, S8, and S11, panels a, b and c, Supporting
Information). To assess binding affinity for the displaced
compounds, competitive ITC experiments were carried out
using inhibitor 2 as the titrant in the presence of fragments 8
and 11, yielding apparent Kd of 2.7 and 4.3 mM for 8 and 11,
respectively (Table 1 and Figure S8 and S11, panel g, Supporting
Information). AmatchingKd of∼5mMwas obtained for 6 under
both direct and competitive conditions, thereby validating the
approach (Figure S6, panels g and h, Supporting Information).
These fragments maintained similar LE values (Table 1) of
the parent inhibitors, which notably fell around the value of
0.24 kcal mol−1 NHA−1 obeying LE’s generally observed for
PPI-targeting small molecules.1
To gain information about the fragments binding mode, we
first turned to group epitope mapping (GEM) characterization
of their STD-NMR spectra.25 Relative degrees of saturation of
the individual protons were normalized to the highest saturated
proton of the compounds, yielding some information of the
proximity of each proton and the interacting protein surface.
The NMR GEM data for compound 6 (Table S2, Supporting
Information, and Figure 4) suggests the protons adjacent to the
hydroxyl group to be in closer contact with the protein, in perfect
agreement with the bindingmode observed in the X-ray structure
(Figure S6, panel i, Supporting Information). In contrast, the
GEM data for 8 and 11 (Tables S3−4, Supporting Information)
could not conclusively inform about their binding modes as
Figure 1. Structural representation of the VCB multiprotein complex
and the pVHL:HIF-1α interface.
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different saturation build up rates are often observed between
aliphatic and aromatic protons.
As no crystal structure could be obtained for compounds 8
and 11, further structural validation of the compounds binding
mode was achieved using 1H−15N heteronuclear single
quantum coherence (HSQC) chemical shift perturbation
(CSP). The backbone assignments for the VCB complex are
available,26 and we experimentally validated our residue-specific
Table 1. Biophysical Characterization of Small Molecules Binding to VCBa
aNMR binding detection was assessed by all three experiments (STD, CPMG, and WaterLOGSY). In all cases, the three experiments were found to
be in agreement with each other; therefore, a single Yes/No answer is tabulated under each set-up. Ⓟ, displaced by 19-mer HIF-1α peptide; *,
obtained by competitive ITC assay; n.d., not determined.
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screening using compound 1 (Figure S2, Supporting
Information)
Being the VCB complex a 42 kDa system and intrinsically
challenging for the majority of protein NMR techniques, an
alternative labeling scheme was adopted. Apart from 15N, the
VCB complex was also perdeuterated. When using this labeling
scheme and for this molecular weight, the yielded spectra
(Figure S8, panel h, Supporting Information) allowed improved
signal-to-noise and less resonance overlap. The expected binding
site of compound 8was successfully confirmed by demonstrating
chemical shifts in the 1H−15N HSQC spectra for residues at
the pVHL-HIF-1α interface as a result of compound titration
(Figure 5a,b).
The recapitulation of the binding site occupied by 8 when it is
part of the Hyp-containing inhibitors confidently reinforces it as
a true fragment hit for this PPI (Figure 5c,d) and is consistent
with the previously observed displacement by the 19-mer HIF-
1α peptide. Taken together our data suggest that Ro3 compliant
native subsite binders (namely, 6, 8, and 11) can be found by
carefully triaged fragment based screening. These hits would
have retrospectively provided key starting points to the design of
1 and 2 even in the absence of information from the natural
peptide ligand.
In summary, this work has addressed for the first time
the problem of detecting and structurally validating the weak
affinities and low ligand efficiencies that are expected for
fragments effectively targeting PPIs. Standard biophysical
fragment screening approaches have been historically optimized
against classical drug targets, such as enzymes and receptors
that typically exhibit LE values well beyond a threshold of
0.3 kcal−1 mol−1 NHA−1. Using a model druggable PPI, we show
that a revision on the experimental conditions of ligand-based
NMR techniques opens the possibility of rescuing genuine
binders, thus delivering more sensitive and robust set-ups for
NMR screening. Screening at higher receptor concentrations
could be particularly beneficial in the case of less stable or more
transient multisubunit complexes, as this would also increase
the relative population of the functional target site. Provided
requirements for compound and protein solubilities are met,
our fine-tuned NMR conditions should yield more accurate hit
rates of true positives. This in turn will enable a more reliable
assessment of PPI target druggability and tractability by fragment
screening and better inform the prioritization of PPI targets for
drug discovery programs.
Figure 2. Binding detection at the pVHL:HIF-1α interface for 4. (a−c)
NMR spectra for VCB + 4 using set-up 1 (red) and the compound alone
(blue). (d) Direct ITC titration for 4 (3 mM compound and 100 μM
VCB). Data was fitted with Ka = 6.7 × 10
3 ± 400 M−1; ΔH = −1450 ±
100 cal/mol; and ΔS = 12.6 cal/mol/degree. (e) Crystal structure of
VCB in complex with 4 (purple carbon sticks). The omit electron
density maps (Fo− Fc) are shown in green contoured at 2.5σ around the
ligand. The protein surface is shown in green at 40% transparency.
Figure 3. Detection of 6 binding to VCB using ligand-based NMR
spectroscopy. (a−c) NMR spectra for VCB + 6 using set-ups 1 and 2, in
red and black respectively, and the compound alone (blue). (d− f)
Spectra for VCB + 6 using set-up 3 (green) and compound alone (blue).
Figure 4. Group epitope mapping (GEM) obtained from STD-NMR
for 6.
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